Skip to main content

Published locations for Hand eczema: Pan-JAK inhibitor delgocitinib shows dose-dependent response in phase 2b trial

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Hand eczema: Pan-JAK inhibitor delgocitinib shows dose-dependent response in phase 2b trial

User login

  • Reset your password
  • /content/hand-eczema-pan-jak-inhibitor-delgocitinib-shows-dose-dependent-response-phase-2b-trial
  • /clinicianreviews/article/231016/psoriasis/hand-eczema-pan-jak-inhibitor-delgocitinib-shows-dose
  • /edermatologynews/article/231016/psoriasis/hand-eczema-pan-jak-inhibitor-delgocitinib-shows-dose
  • /familypracticenews/article/231016/psoriasis/hand-eczema-pan-jak-inhibitor-delgocitinib-shows-dose
  • /internalmedicinenews/article/231016/psoriasis/hand-eczema-pan-jak-inhibitor-delgocitinib-shows-dose
  • /internalmedicine/article/231016/psoriasis/hand-eczema-pan-jak-inhibitor-delgocitinib-shows-dose
  • /dermatology/article/231016/psoriasis/hand-eczema-pan-jak-inhibitor-delgocitinib-shows-dose-dependent
  • /familymedicine/article/231016/psoriasis/hand-eczema-pan-jak-inhibitor-delgocitinib-shows-dose